Novabay Pharmaceuticals Inc Beta
What is the Beta of Novabay Pharmaceuticals Inc?
The Beta of Novabay Pharmaceuticals Inc is 0.00
What is the definition of Beta?
BETA indicates whether a stock is more or less volatile than the market as a whole. A beta less than 1 indicates that the stock is less volatile than the market, while a beta more than 1 indicates that the stock is more volatile. Volatility is measured as the fluctuation of the price around the mean.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta of companies in the Health Care sector on NYSEMKT compared to Novabay Pharmaceuticals Inc
What does Novabay Pharmaceuticals Inc do?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Companies with beta similar to Novabay Pharmaceuticals Inc
- Vision Marine Technologies has Beta of 0.00
- Ely Gold Royalties has Beta of 0.00
- Glacier Lake Resources has Beta of 0.00
- Magnum Mining and Exploration has Beta of 0.00
- Africa Opportunity Fund has Beta of 0.00
- Fulcrum Utility Services has Beta of 0.00
- Novabay Pharmaceuticals Inc has Beta of 0.00
- Gullewa has Beta of 0.00
- S.A.L. Steel has Beta of 0.00
- Andina Acquisition III has Beta of 0.00
- Andina Acquisition III has Beta of 0.00
- Brilliant Acquisition has Beta of 0.00
- Indokem has Beta of 0.00